ABILIFY ASIMTUFII 720 MG/2.4 ML

What it is

ABILIFY ASIMTUFII 720 MG/2.4 ML is how the CMS NADAC file names this product. The FDA NDC Directory lists it as aripiprazole, under the trade name “Abilify Asimtufii”.

FDA gives its dosage form as injection, suspension, extended release and its route as intramuscular.

The labeler, the company named on the label, is Otsuka America Pharmaceutical, Inc.

FDA’s Established Pharmacologic Class for it is Atypical Antipsychotic.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 59148-0102-80.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $4,284.54 for 2.4 mL (2.4 × $1,785.22689 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

The NDC

• 59148-0102-80 · Otsuka America Pharmaceutical, Inc · $1,785.22689 per ML · eff. 2026-09-23 filed

Other strengths, forms and brands

20 other products in the NADAC file share the FDA nonproprietary name aripiprazole with ABILIFY ASIMTUFII 720 MG/2.4 ML.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

Its NADAC price is $1,785.22689 per ML filed.

Of the 25 other products in FDA’s Atypical Antipsychotic class priced per ML, 16 have a higher middle NADAC price and 9 a lower one. The one in the middle is INVEGA SUSTENNA 39 MG/0.25 ML, at $2,338.748 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $4,234.17 for 2.4 mL, at an average of $1,764.23642 per ML in 2024 (2024-01-01 to 2024-12-31) for “Abilify Asimtufii” and “Aripiprazole”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 11,621 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 2.4 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 2.4 mL; your package may hold a different amount.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.